Revolution Medicines Inc
RVMDHealthcare|Biotechnology|USA
$186.89
-4.33 (-2.26%)
Tangible Book
$7.14
Clinical Trials (21)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07491445 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Pancreatic Cancer, Pancreatic Cancer Metastatic | P3 | Recruiting | 900 | RCT, Open-label | daraxonrasib, gemcitabine, nab-paclitaxel |
| NCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, PDAC | P3 | Active | 500 | RCT, Open-label | RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin |
| NCT07621718 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) | Pancreatic Cancer, Pancreatic Cancer Metastatic | P3 | Recruiting | 670 | RCT, Double-blind | Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), Nab-paclitaxel |
| NCT06881784 Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer | P3 | Recruiting | 590 | RCT, Open-label | daraxonrasib, docetaxel |
| NCT07252232 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, PDAC | P3 | Recruiting | 500 | RCT, Open-label | daraxonrasib |
| NCT05379985 Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | P1P2 | Recruiting | 754 | Open-label | RMC-6236 |
| NCT06162221 Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC | P1P2 | Recruiting | 616 | Open-label | RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, RMC-9805 |
| NCT06922591 Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | P1P2 | Recruiting | 183 | Open-label | TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel |
| NCT06128551 Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer | P1P2 | Recruiting | 534 | Open-label | Elironrasib, Daraxonrasib |
| NCT07397338 Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Advanced Solid Tumors, Metastatic Solid Tumors | P1P2 | Recruiting | 370 | Open-label | Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only), Daraxonrasib (Cohort B1 only) |
| NCT06445062 Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Colorectal Cancer, CRC | P1P2 | Recruiting | 1,130 | Open-label | RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805 |
| NCT06040541 Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | P1 | Recruiting | 604 | Open-label | RMC-9805, RMC-6236 |
| NCT05462717 Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | P1 | Active | 222 | Open-label | RMC-6291 |
| NCT07349537 Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | P1 | Recruiting | 574 | Open-label | RMC-5127, daraxonrasib, cetuximab |
| NCT04418661 Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies | Metastatic Neoplasm | P1P2 | Terminated | 65 | Open-label | Vociprotafib, Pembrolizumab, Adagrasib |
| NCT05054725 Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Non-Small Cell Lung Cancer | P2 | Completed | 47 | Open-label | RMC-4630, Sotorasib |
| NCT03989115 Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC | Solid Tumor | P1P2 | Completed | 113 | Open-label | RMC-4630, Cobimetinib, Drug: Osimertinib |
| NCT03634982 Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | Solid Tumors | P1 | Unknown | 133 | Open-label | RMC-4630 |
| NCT04774952 Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors | Solid Tumors | P1 | Completed | 58 | Open-label | RMC-5552 |
| NCT05557292 RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | Glioblastoma, Recurrent Glioblastoma | P1 | Terminated | 7 | Open-label | RMC-5552 |
| NCT07573215 Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | AVAILABLE | — | — | daraxonrasib |